An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants (FIGARO-BM)
A Non-blinded Retrospective Biomarker add-on Study to FIGARO-DKD for Bioprofiling the Pharmacodynamic Response to Finerenone in FIGARO-DKD Subjects
Sponsor: Bayer
Listed as NCT05013008, this PHASE2 trial focuses on Chronic Kidney Disease and Type 2 Diabetes Mellitus and remains completed. Sponsored by Bayer, it has been updated 11 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Oct 2023 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Feb 2022 — Apr 2023 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aarhus N, Denmark , Anyang-si, South Korea , Arkhangelsk, Russia , Asheboro, United States , Ashkelon, Israel , Barcelona, Spain , Bergamo, Italy , Bologna, Italy , Boston, United States and 88 more locations